Detalhe da pesquisa
1.
Immune checkpoint therapy-current perspectives and future directions.
Cell
; 186(8): 1652-1669, 2023 04 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37059068
2.
Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy.
Cell
; 179(5): 1177-1190.e13, 2019 Nov 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31730856
3.
Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade.
Cell
; 155(6): 1309-22, 2013 Dec 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-24315100
4.
Development of a Strategic Initiative at MD Anderson Cancer Center to Improve Outcomes in Immune-Related Adverse Events.
J Natl Compr Canc Netw
; : 1-8, 2024 Jan 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38190801
5.
Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities.
Proc Natl Acad Sci U S A
; 116(44): 22246-22251, 2019 10 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-31611368
6.
Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial.
Lancet Oncol
; 20(10): 1432-1443, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31515154
7.
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities.
Proc Natl Acad Sci U S A
; 113(42): 11919-11924, 2016 10 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-27698113
8.
Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting.
Prostate
; 77(2): 123-144, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27679977
9.
Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg?
Curr Opin Urol
; 27(6): 566-571, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28825923
10.
New approaches to immunotherapy for metastatic castration-resistant prostate cancer.
Clin Adv Hematol Oncol
; 17(5): 283-286, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-31188806
11.
Molecular pathways and cellular subsets associated with adverse clinical outcomes in overlapping immune-related myocarditis and myositis.
Cancer Immunol Res
; 2024 May 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38768394
12.
Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series.
Clin Cancer Res
; 30(10): 2272-2285, 2024 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38488813
13.
A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer.
Clin Cancer Res
; 2024 Apr 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38683200
14.
Patient-Derived Xenograft Tumor Models: Overview and Relevance to IR.
J Vasc Interv Radiol
; 29(6): 880-882.e1, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29798759
15.
A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study.
Lancet Oncol
; 13(11): 1105-13, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23059047
16.
Cardiometabolic healthcare for men with prostate cancer: an MD Anderson Cancer Center experience.
Cardiooncology
; 9(1): 33, 2023 Sep 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37705024
17.
Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials.
Clin Cancer Res
; 29(13): 2426-2434, 2023 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37058234
18.
Evaluation of the Aggressive-Variant Prostate Cancer Molecular Signature in Clinical Laboratory Improvement Amendments (CLIA) Environments.
Cancers (Basel)
; 15(24)2023 Dec 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38136389
19.
Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor).
J Immunother Cancer
; 11(3)2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36948506
20.
Anti-PD-L1 plus enzalutamide does not improve overall survival in prostate cancer.
Cell Rep Med
; 3(4): 100613, 2022 04 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35492243